TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24019544
Drug: Panobinostat 20
Normalized name: panobinostat 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat 20 mg plus bortezomib 1.3 mg/m(2) (MTD) in the escalation phase
Study: 24022390
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg daily in three divided doses (control)
Study: 24023466
Drug: Omega-3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplementation (2 g/day)
Study: 24023652
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion test
Study: 24023652
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion test in patients with good hypoglycaemia awareness
Study: 24023652
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion test in patients with poor hypoglycaemia awareness
Study: 24024534
Drug: Quetiapine (flexibly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (flexibly dosed at 400-800 mg/day, with options to reduce to 200 mg/day based on tolerability)
Study: 24025627
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions (carrot juice, NaCl, caffeine, urea)
Study: 24025631
Drug: Potassium excretion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium excretion measurement
Study: 24025631
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of potassium excretion by race
Study: 24025631
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of potassium excretion by education level
Study: 24025631
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of potassium excretion by income level
Study: 24028306
Drug: Intervention: Intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs (diuretic, ACE inhibitors, β-adrenergic blocking agent, calcium channel blocking agent) if BP >130/80 mmHg.
Study: 24028306
Drug: Intervention: Intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Intensification of lifestyle changes and sequential prescription of antihypertensive drugs.
Study: 24028677
Drug: Omalizumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (75 or 150 mg in a pre-filled syringe) at 2 or 4 week intervals for 24 weeks
Study: 24028749
Drug: Etonogestrel contraceptive
Normalized name: Etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel contraceptive implant placed within 15 min of mifepristone administration
Study: 24030098
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg daily on days 1-21 every 28 days until progressive disease or intolerability
Study: 24030879
Drug: IPTp with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPTp with sulfadoxine/pyrimethamine (SP) given twice during pregnancy
Study: 24030918
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 30 or 40 mg/m² intravenously on day 1; dexamethasone 40 mg orally on days 1-4; lenalidomide 25 mg orally on days 1-21, administered every 28 days
Study: 24030918
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with lenalidomide
Study: 24030928
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) with protease inhibitors (PIs)
Study: 24032456
Drug: Ofatumumab 300
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 300 mg IV on Day 1, followed by seven weekly IV infusions of 1000 mg.
Study: 24034562
Drug: Carbon ion
Normalized name: CARBON ION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbon ion radiotherapy combined with weekly gemcitabine and adjuvant gemcitabine
Study: 24035405
Drug: Tremelimumab 15
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 15 mg/kg intravenously once every 90 days until progressive disease or severe toxicity
Study: 24037550
Drug: Herpes zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herpes zoster vaccine (Zostavax)
Study: 24037866
Drug: Community-directed treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-directed treatment (ComDT) added to health facility (HF) approach
Study: 24037867
Drug: Non-recommended antimalarials
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-recommended antimalarials
Study: 24038364
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulfadoxine/pyrimethamine (IPTi-SP)
Study: 24045608
Drug: Intravenous amantadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amantadine sulfate 200 mg
Study: 24048627
Drug: Sunitinib 25
Normalized name: sunitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 25 mg daily
Study: 24048627
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg daily
Study: 24048627
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiation therapy (50.4 Gy in 28 fractions)
Study: 24048673
Drug: GLP-1 co-infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 co-infusion during hyperglycaemic clamps
Study: 24048673
Drug: GIP co-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIP co-infusion during hyperglycaemic clamps
Study: 24048673
Drug: Saline co-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline co-infusion during hyperglycaemic clamps
Study: 24050953
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily orally until unacceptable toxicity or disease progression
Study: 24050955
Drug: Post-diagnostic β-blocker
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-diagnostic β-blocker use
Study: 24050955
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no β-blocker use)
Study: 24052462
Drug: Once-monthly continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-monthly continuous erythropoietin receptor activator (CERA)
Study: 24053191
Drug: Lanreotide Autogel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel, 120 mg every 28 days over ≤92 weeks
Study: 24055176
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with various treatments for T2DM
Study: 24056477
Drug: Universal MRSA
Normalized name: STATLOCK UNIVERSAL PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal MRSA screening with contact precautions and decolonisation (intranasal mupirocin and chlorhexidine bathing)
Study: 24056477
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enhanced hand hygiene and MRSA screening with contact precautions and decolonisation
Study: 24058078
Drug: Paclitaxel-iopromide-coated balloon
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²)
Study: 24058078
Drug: Paclitaxel-iopromide-coated balloon
Normalized name: Iopromide
DrugBank: Iopromide (DB09156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²) + Bare metal stent (BMS)
Study: 24059479
Drug: Balanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced solution (BS) group
Study: 24059479
Drug: Unbalanced solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unbalanced solution (UBS) group
Study: 24062399
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy for cancer
Study: 24062399
Drug: Low Instrumental
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Instrumental Activities of Daily Living (IADL) scores
Study: 24062895
Drug: NT-proBNP levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP levels below median (5000 pg/ml)
Study: 24063698
Drug: Olaparib 200
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle
Study: 24064228
Drug: Cooling initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling initiated with surface cooling pads, followed by 1000-2000 mL of cold saline at hospital arrival and endovascular cooling in the catheterisation laboratory.
Study: 24064318
Drug: Partial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT) to a prescribed dose of 38.5 Gy in 10 fractions.
Study: 24064318
Drug: Partial breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT).
Study: 24065152
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (weight gain >4%)
Study: 24065152
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy (weight gain no or little)
Study: 24068762
Drug: Pharmacist prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist prescribing intervention (10 units of insulin glargine at bedtime, adjusted by increments of 1 unit daily)
Study: 24070065
Drug: aPC infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aPC infusion (24 mcg/kg/h for 96 hours)
Study: 24073008
Drug: Ayurvedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayurvedic treatment
Study: 24075534
Drug: Bortezomib 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.2 mg/m(2) and idarubicin 8 mg/m(2)
Study: 24075534
Drug: Bortezomib 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 0.8 mg/m(2) and idarubicin 10 mg/m(2)
Study: 24075534
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m(2) and idarubicin 10 mg/m(2)
Study: 24075534
Drug: Bortezomib and
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib and idarubicin combination
Study: 24075891
Drug: Capsule endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule endoscopy (CE)
Study: 24076532
Drug: Left atrial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left atrial volume index (LAVi) ≥32 ml/m²
Study: 24076532
Drug: LAVi ≥32
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAVi ≥32 ml/m²
Study: 24076532
Drug: LAVi <32
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAVi <32 ml/m²
Study: 24076699
Drug: Nonanimal stabilized
Normalized name: nonanal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonanimal stabilized hyaluronic acid gel (mean of 163 ml per buttock)
Study: 24076699
Drug: Nonanimal stabilized
Normalized name: nonanal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonanimal stabilized hyaluronic acid gel
Study: 24077846
Drug: Imatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib plus sequential chemotherapy followed by autologous stem cell transplantation
Study: 24077916
Drug: Neratinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (200 mg/day) with trastuzumab (4 mg/kg IV loading dose, then 2 mg/kg IV weekly) and paclitaxel (80 mg/m2 IV days 1, 8, and 15 of a 28-day cycle)
Study: 24077916
Drug: Neratinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neratinib (120 up to 240 mg/day) with trastuzumab and paclitaxel
Study: 24079262
Drug: Physical examination
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical examination to guide fluid therapy
Study: 24079716
Drug: Rotarix (RIX4414)
DrugBank: Rotavirus vaccine (DB10276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix (RIX4414) - two doses (0, 2-month schedule)
Study: 24079992
Drug: PRIME intervention
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRIME intervention (Health Centre Management, Fever Case Management, Patient-Centered Services, support for supplies of malaria diagnostics and antimalarial drugs)
Study: 24081577
Drug: Clofarabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofarabine (20 mg/m² × 5 days) plus low-dose cytarabine (20 mg/m² × 14 days)
Study: 24089587
Drug: Infliximab (IFX)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab (IFX) 5 mg/kg every 6 weeks for 56 weeks, then reduced to 3 mg/kg every 8 weeks during the second year, with concomitant MTX at median dose 7.5 mg/week.
Study: 24090033
Drug: Home administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home administration of pemetrexed maintenance therapy (500 mg/m² every 3 weeks until progressive disease or unacceptable toxicity)
Study: 24090077
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral dose of DMAA
Study: 24092933
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m² for 7 days) and Gemtuzumab ozogamicin (3 mg/m² on day 8)
Study: 24093426
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg CHP-NY-ESO-1 vaccine
Study: 24093426
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg CHP-NY-ESO-1 vaccine
Study: 24095247
Drug: Setipiprant capsule
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant capsule (2 250-mg capsules)
Study: 24095247
Drug: Setipiprant tablet
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant tablet (500-mg tablet)
Study: 24097022
Drug: Step 1
Normalized name: Nicotine Patch Step 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 1 analgesic (mainly paracetamol)
Study: 24097022
Drug: Step 2
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 2 analgesic (23% dextropropoxyphene and 40.3% tramadol/paracetamol combination)
Study: 24097022
Drug: Step 3
Normalized name: Nicotine Patch Step 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step 3 analgesics
Study: 24097022
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic medication
Study: 24098507
Drug: Netazepide (YF476)
Normalized name: Netazepide
DrugBank: Netazepide (DB12355)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide (YF476) administered orally for 12 weeks
Study: 24099345
Drug: Thrice-weekly rifampicin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly rifampicin-based therapy
Study: 24099518
Drug: T4 immunotherapy
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 immunotherapy (T4(+) T-cells) administered intratumorally at doses starting from 10^7 cells to 10^9 cells.
Study: 24099518
Drug: T4 immunotherapy
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: T4 immunotherapy (T4(+) T-cells) administered intratumorally with low- or high-dose cyclophosphamide before 10^9 T4(+) T-cells.
Study: 24099585
Drug: Cabazitaxel (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (12 mg/m²)
Study: 24099585
Drug: Cabazitaxel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (10 mg/m²)
Study: 24099585
Drug: Cabazitaxel (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (weekly administration)
Study: 24099585
Drug: Cabazitaxel (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (6-12 mg/m² doses)
Study: 24099865
Drug: Oxaliplatin 120
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 120 mg/m² and pemetrexed 500 mg/m² intravenously every 21 days
Study: 24100924
Drug: Erlotinib (dose-intense)
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib (dose-intense)
Study: 24101373
Drug: Tafamidis 20
Normalized name: TAFAMIDIS 20MG TAB UD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 20 mg QD for 12 months
Study: 24102029
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (treated with statins)
Study: 24105751
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 1,000 mg every 3 days
Study: 24106815
Drug: Active infusion
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active infusion of ropivacaine 0.2% at 5 mL/hr via TAP catheter
Study: 24106815
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion via TAP catheter
Study: 24106841
Drug: Living with
Normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living with Hope Program (self-administered intervention including a film and a hope activity)
Study: 24106922
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 1.8-2.0 ml of 0.75% ropivacaine plus 10 μg of fentanyl
Study: 24108117
Drug: Severe sepsis
Normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe sepsis treatment (no specific intervention details provided)
Study: 24109561
Drug: Internet-administered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-administered treatment based on guided physical exercise for Major Depressive Disorder (MDD)
Study: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2, days 2-15
Study: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) 75 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Study: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Study: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 100 mg/m2, Capecitabine (CAP) 1600 mg/m2
Study: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) 150 mg/m2
Study: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IRIN) 100 mg/m2
Study: 24114613
Drug: FOLFIRI-B chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI-B chemotherapy
Study: 24114964
Drug: Platinum-based doublet
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based doublet therapy (carboplatin plus paclitaxel)
Study: 24117272
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (radiochemotherapy)
Study: 24118452
Drug: Anagrelide (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide (starting dose 1 mg/d in 52.6% of patients; 0.5 mg/d in 41.1%)
Study: 24118452
Drug: Anagrelide after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide after discontinuing previous cytoreductive therapy (CRT)
Study: 24119590
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart added to existing basal insulin (n=519)
Study: 24119590
Drug: Switched from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switched from biphasic insulin (n=947)
Study: 24119590
Drug: Insulin-naïve begun
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-naïve begun with basal plus insulin aspart (n=1594)
Study: 24120120
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 fortified bread (125 μg daily) for 1 year
Study: 24120338
Drug: Endoscopic hemostatic
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic hemostatic powder (21 g applied during endoscopy)
Study: 24120380
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg, 150 mg, 225 mg, and 300 mg given orally once daily for 27 days
Study: 24122237
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment during childhood
Study: 24122387
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly (part I)
Study: 24122387
Drug: Lenalidomide 10
Normalized name: lenalidomide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly plus rituximab 375 mg/m2 (part II)
Study: 24122387
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (lenalidomide, low-dose dexamethasone, and rituximab)
Study: 24123804
Drug: Platelet counts
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet counts < 60 × 10(9) /L on postoperative day 5 (POD5)